Sensyne and OMNY to Collaborate on Proposals for Healthcare Providers to Use Real-World Data and Advanced Analytical Tools to Improve Patient Outcomes and Accelerate New Drug Development
Sensyne Health plc, the clinical AI company, and OMNY Health, a leading US-based real-world data company, have announced a strategic team relationship. The agreement establishes a flexible framework within which Sensyne can subscribe to data offerings through the OMNY health platform, which includes more than 22 million anonymized patient records across broad therapeutic areas in support of the work. Sensyne data analytics for life science companies. In addition, Sensyne and OMNY have agreed to work together on business projects for life science clients to advance and accelerate ethical medical research. By offering biopharmaceutical customers a joint offering with real-world data from OMNY and machine learning expertise from Sensyne, the two companies – and their healthcare system partners – will have more opportunities to support important research. in life sciences.
The OMNY Data Network complements Sensyne’s existing global medical research dataset of 22.1 million patients, sourced from ethical sources through strategic partnerships with U.S. Health Systems and National Health Service (NHS ) from the United Kingdom. With representation from more than 50,000 vendors in 40 states, the OMNY healthcare platform also offers data control, security and governance to maximize the usefulness of information while maintaining compliance with US regulations. Sensyne will now have a new way to access OMNY’s catalog data from over 22 million unique patient records, dramatically improving the scale of real-world data on which Sensyne can apply its advanced machine learning and bringing the possible combined total of anonymized patient data available for collaborative research to more than 44 million patients.
Derek Baird, President, North America, Sensyne Health said, “This relationship was forged on a mutual belief in the power of real world data to support revolutionary ideas and discoveries. The OMNY team, like us, appreciate the complexity of working with longitudinal clinical records and the trust health systems place in our companies to analyze anonymized patient data in an ethical, secure and responsible manner. We share common philosophies and missions, as well as complementary approaches in the responsible use of real world data to accelerate life science research for our clients. This is an exciting alliance and we are delighted to be working together.
Mitesh Rao, MD, CEO, OMNY Health said, “OMNY Health is seizing the opportunity to work with the world-class machine learning team and data science professionals at Sensyne Health and is delighted that Sensyne is joining the platform. We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real-world data partnerships in the life science industry. This collaboration with Sensyne Health creates even more opportunities to apply emerging technologies to the unprecedented data we have gathered, enabling both companies to ethically innovate on behalf of our respective partners and, most importantly, create better results. for patients.
Sensyne works with life science partners on different types of research projects in several pathological fields. Actionable insights from OMNY’s longitudinal patient datasets will help them with synthetic control arms, patient stratification, patient identification and selection, as well as important clinical trial design decisions from OMNY. late phase, marketing and economic pricing of health.
Want the latest science news delivered straight to your inbox? Become a Free SelectScience Member Today >>